ABVC BioPharma (ABVC) Proxy filing summary

Executive summary

• Special shareholder meeting scheduled for September 18, 2026, to be held virtually, with participation and voting instructions provided for all shareholders.

• Three key proposals will be presented: approval of the 2026 Equity Incentive Plan, ratification of equity awards granted since February 16, 2026, and authorization for potential issuance of shares for a land acquisition in Taiwan.

• Board of Directors unanimously recommends voting in favor of all proposals.

• Shareholders of record as of July 24, 2026, are entitled to vote, with a total of 26,554,365 shares outstanding.

Voting matters and shareholder proposals

• Proposal 1: Approve the 2026 Equity Incentive Plan, which replaces the 2016 Plan and introduces a new formula for share allocation and an evergreen provision for annual increases.

• Proposal 2: Ratify equity awards granted since February 16, 2026, to maintain continuity in the equity compensation program.

• Proposal 3: Authorize issuance of up to 6,638,591 shares (or equivalents) at not less than $1.00 per share for a land acquisition in Taiwan, in compliance with Nasdaq Listing Rule 5635(d).

• Each proposal requires a majority of votes cast for approval.

Board of directors and corporate governance

• Board members and officers may solicit proxies by mail, phone, or in person, with no additional compensation.

• Board retains authority to determine final terms of the land acquisition and related share issuance, within shareholder-approved parameters.